22:41 EDT Sarepta (SRPT) drops another 5% to $13.37 after downgrades, FDA probe
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- FDA investigating risk of acute liver failure with Sarepta gene therapies
- Sarepta downgraded to Sell from Hold at Deutsche Bank
- Sarepta downgraded to Market Perform from Outperform at Leerink
- Top 3 Trending Stocks, According to Analysts – 7/18/2025
- Sarepta downgraded to Neutral from Outperform at Baird